Skip to main content

Table 1 Basic characteristics between 5-ARIs User and comparison groups with Bladder Cancer (n = 5214)

From: 5α-reductase inhibitors impact prognosis of urothelial carcinoma

  5-ARIs User, n (%) None User, n (%) P-value
Case No. 474 4740  
Variables
 Age (Mean ± SD) 76.47 (±7.90) 76.60 (±8.51) 0.733
Age category (n, %)
 < 65 42 (8.86) 466 (9.83)  
 65–74 153 (32.28) 1387 (29.26)  
 > 75 279 (58.86) 2887 (60.91)  
 CCI score (Mean ± SD) 4.23 (±2.18) 4.22 (±2.22) 0.959
CCI score category
 0 ~ 3 220 (46.41) 2203 (46.48)  
 4 ~ 7 202 (42.62) 2037 (42.97)  
 8+ 52 (10.97) 500 (10.55)  
Comorbidity
 Hypertension 258 (54.43) 2546 (53.71) 0.765
 Hyperlipidemia 88 (18.57) 842 (17.76) 0.664
 Diabetes mellitus 114 (24.05) 1121 (23.65) 0.845
 Chronic Kidney Disease 36 (7.59) 378 (7.97) 0.771
  1. CCI Charlson Comorbidity Index